Elsevier

The Lancet

Volume 339, Issue 8806, 6 June 1992, Pages 1375-1377
The Lancet

ORIGINAL ARTICLES
Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease

https://doi.org/10.1016/0140-6736(92)91196-FGet rights and content

Abstract

The pathogenesis of Parkinson's disease may be influenced by genetic and environmental factors. Cytochrome P450 mono-oxygenases help to protect against toxic environmental compounds and individual variations in cytochrome P450 expression might, therefore, influence susceptibility to environmentally linked diseases. The frequency of mutant CYP2D6 alleles was studied in 229 patients with Parkinson's disease and 720 controls. Individuals with a metabolic defect in the cytochrome P450 CYP2D6-debrisoquine hydroxylase gene with the poor metaboliser phenotype had a 2·54-fold (95% Cl 1·51-4·28) increased risk of Parkinson's disease. Determination of CYP2D6 phenotype and genotype may help to identify those at greatest risk of Parkinson's disease and may also help to identify the environmental or metabolic agents involved in the pathogenesis of this disease.

References (35)

  • Cr Wolf

    Metabolic factors in cancer susceptibility

    Cancer Surv

    (1990)
  • Lj Golbe

    The genetics of Parkinson's disease

    Neurology

    (1990)
  • Wg Johnson

    Genetic susceptibility to Parkinson's disease

    Neurology

    (1991)
  • Da Price-Evans et al.

    A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population

    J Med Genet

    (1980)
  • Ac Gough et al.

    Identification of the primary gene defect at the cytochrome P450 CYP2D6 locus

    Nature

    (1990)
  • N. Hanioka et al.

    The human CYP2D6 locus associated with a common genetic defect in drug oxidation: a G1943 to A base change in intron 3 of a mutant CYP2D6 allele results in an aberrrant 3' splice recognition site.

    Am J Hum Genet

    (1990)
  • A. Gaedigk et al.

    Deletion of the entire CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism

    Am J Hum Genet

    (1991)
  • Cited by (440)

    • Association of cytochrome P2D6 gene polymorphism with the susceptibility of Egyptian patients to systemic sclerosis disease

      2021, Meta Gene
      Citation Excerpt :

      Patients full medical histories were taken and the physical examinations were carried out, including: general, cutaneous, vascular, musculoskeletal, pulmonary, cardiac, gastrointestinal, and neurological examinations.Tests were conducted, including renal, liver function tests, antinuclear antibody (ANA) titer and pattern, anti scleroderma 70, high-resolution computer tomography (HRCT), pulmonary function tests (PFT), and cardiac echocardiography. CYP2D6 gene alleles (CYP2D6 *1, CYP2D6 *3, and CYP2D6 *4) were determined according to the technique described by Smith et al. (Smith et al., 1992), using the PCR-RFLP (polymerasechain reaction-restriction fragment length polymorphism) method. Genomic DNAwas isolated from the peripheral blood leukocytes using the mini kit purchased from INTRONBIO (ANALSIS) Catalog No: 17045.

    • The relationship between plasma concentration of metoprolol and CYP2D6 genotype in patients with ischemic heart disease

      2014, Pharmacological Reports
      Citation Excerpt :

      Each subject agreed to sign a written informed consent. The blood samples were analyzed for two major defective alleles for the CYP2D6 gene – CYP2D6*4 and CYP2D6*3 – by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method according to the procedure proposed by Smith et al. [8]. DNA was arranged from leukocytes extracted from peripheral blood.

    • CYP2D6 phenotypes and Parkinson's disease risk: A meta-analysis

      2014, Journal of the Neurological Sciences
      Citation Excerpt :

      Meta-regression analysis showed that the source of the controls was the major factor contributing to heterogeneity (regression coefficient = − 0.263; 95%CI: − 472–0.053; P = 0.015). When the sensitivity analysis was conducted, our results indicated that the study by Smith [7] apparently influenced the overall results. After excluding that study from the analysis, the pooled ORs (95%CI) of the remaining studies were still insignificant (OR: 1.03, 95%CI: 0.95–1.12; P = 0.515), and there was still significant heterogeneity (I2 = 32.0%, P = 0.002).

    View all citing articles on Scopus
    View full text